Abstract
This systematic review evaluates the prevalence of long-term complications of serogroup B meningococcal disease (MD) in light of the recent licensure of a vaccine against meningococcal B disease. Twelve appropriate studies were identified by searching available databases from 1946 to July 2014. The average prevalence of hearing impairment was 4.2% among serogroup B MD survivors; 2.3% suffered amputation and 2.3% developed seizures. When compared with complications due to non-meningococcal B bacterial meningitis, physical impairment and seizures were more common in survivors of meningococcal B disease but hearing impairment had similar prevalence. Few studies quantified less frequent complications such as visual impairment and cognitive dysfunction. Better comprehensive reporting of the complications and costs of serogroup B MD in survivors and their families is needed to inform vaccination policy.
Keywords: Complications, meningococcal disease, serogroup B.
Infectious Disorders - Drug Targets
Title:Complications of Serogroup B Meningococcal Disease in Survivors: A Review
Volume: 14 Issue: 3
Author(s): Fereshteh Dastouri, Ahmad Mirmohammad Hosseini, Elizabeth Haworth, Gulam Khandaker, Harunor Rashid and Robert Booy
Affiliation:
Keywords: Complications, meningococcal disease, serogroup B.
Abstract: This systematic review evaluates the prevalence of long-term complications of serogroup B meningococcal disease (MD) in light of the recent licensure of a vaccine against meningococcal B disease. Twelve appropriate studies were identified by searching available databases from 1946 to July 2014. The average prevalence of hearing impairment was 4.2% among serogroup B MD survivors; 2.3% suffered amputation and 2.3% developed seizures. When compared with complications due to non-meningococcal B bacterial meningitis, physical impairment and seizures were more common in survivors of meningococcal B disease but hearing impairment had similar prevalence. Few studies quantified less frequent complications such as visual impairment and cognitive dysfunction. Better comprehensive reporting of the complications and costs of serogroup B MD in survivors and their families is needed to inform vaccination policy.
Export Options
About this article
Cite this article as:
Dastouri Fereshteh, Mirmohammad Hosseini Ahmad, Haworth Elizabeth, Khandaker Gulam, Rashid Harunor and Booy Robert, Complications of Serogroup B Meningococcal Disease in Survivors: A Review, Infectious Disorders - Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871526515999150320155614
DOI https://dx.doi.org/10.2174/1871526515999150320155614 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetically Engineered Stem Cells for Therapeutic Gene Delivery
Current Gene Therapy Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets CGRP-Receptor Antagonism in Migraine Treatment
CNS & Neurological Disorders - Drug Targets Central G-Protein Coupled Receptors (GPCR)s as Molecular Targets for the Treatment of Obesity: Assets, Liabilities and Development Status
Current Drug Targets - CNS & Neurological Disorders Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design The Possibilities and Pitfalls for Anti-Complement Therapies in Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy GABAergic Drugs for the Treatment of Migraine
CNS & Neurological Disorders - Drug Targets Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Cellular Model of Alzheimer's Disease: Aβ1-42 Peptide Induces Amyloid Deposition and a Decrease in Topo Isomerase IIβ and Nurr1 Expression
Current Alzheimer Research The Possible Involvement of HLA Class III Haplotype (RAGE, HSP70 and TNF Genes) in Alzheimer's Disease
Current Alzheimer Research Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Current Gene Therapy Techniques and Methods for In Vivo MRI Monitoring of Exogenous and Endogenous Neural Stem Cell-Mediated Brain Repair
Recent Patents on Regenerative Medicine Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine
Current Medicinal Chemistry Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Current Topics in Medicinal Chemistry